JP2016104000A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016104000A5 JP2016104000A5 JP2015223865A JP2015223865A JP2016104000A5 JP 2016104000 A5 JP2016104000 A5 JP 2016104000A5 JP 2015223865 A JP2015223865 A JP 2015223865A JP 2015223865 A JP2015223865 A JP 2015223865A JP 2016104000 A5 JP2016104000 A5 JP 2016104000A5
- Authority
- JP
- Japan
- Prior art keywords
- arylsulfatase
- composition
- chromatography
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100022146 Arylsulfatase A Human genes 0.000 claims 20
- 108010036867 Cerebroside-Sulfatase Proteins 0.000 claims 20
- 238000000034 method Methods 0.000 claims 16
- 239000000203 mixture Substances 0.000 claims 11
- 150000001413 amino acids Chemical group 0.000 claims 6
- 238000004587 chromatography analysis Methods 0.000 claims 4
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 150000007523 nucleic acids Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 238000001042 affinity chromatography Methods 0.000 claims 2
- 229940024606 amino acid Drugs 0.000 claims 2
- 238000011210 chromatographic step Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims 2
- 238000004255 ion exchange chromatography Methods 0.000 claims 2
- 239000000644 isotonic solution Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 238000003259 recombinant expression Methods 0.000 claims 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims 1
- 101710115233 Arylsulfatase D Proteins 0.000 claims 1
- 102100033887 Arylsulfatase D Human genes 0.000 claims 1
- 102000009133 Arylsulfatases Human genes 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 238000005119 centrifugation Methods 0.000 claims 1
- 238000009295 crossflow filtration Methods 0.000 claims 1
- 238000011026 diafiltration Methods 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 238000001704 evaporation Methods 0.000 claims 1
- 230000008020 evaporation Effects 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 239000012537 formulation buffer Substances 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 239000007972 injectable composition Substances 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 239000011148 porous material Substances 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 229960001153 serine Drugs 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 230000001954 sterilising effect Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 108060007951 sulfatase Proteins 0.000 claims 1
- 239000006228 supernatant Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000000108 ultra-filtration Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200600488 | 2006-04-04 | ||
| DKPA200600488 | 2006-04-04 | ||
| DKPA200600922 | 2006-07-05 | ||
| DKPA200600922 | 2006-07-05 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013123735A Division JP2013236633A (ja) | 2006-04-04 | 2013-06-12 | ポリペプチドの濃縮方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016104000A JP2016104000A (ja) | 2016-06-09 |
| JP2016104000A5 true JP2016104000A5 (enExample) | 2016-08-25 |
Family
ID=38472949
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009503414A Pending JP2009532394A (ja) | 2006-04-04 | 2007-04-04 | ポリペプチドの濃縮方法 |
| JP2009162789A Active JP5384232B2 (ja) | 2006-04-04 | 2009-07-09 | ポリペプチドの濃縮方法 |
| JP2013123735A Pending JP2013236633A (ja) | 2006-04-04 | 2013-06-12 | ポリペプチドの濃縮方法 |
| JP2013207384A Active JP5878152B2 (ja) | 2006-04-04 | 2013-10-02 | ポリペプチドの濃縮方法 |
| JP2013207365A Withdrawn JP2014058521A (ja) | 2006-04-04 | 2013-10-02 | ポリペプチドの濃縮方法 |
| JP2015223865A Pending JP2016104000A (ja) | 2006-04-04 | 2015-11-16 | ポリペプチドの濃縮方法 |
Family Applications Before (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009503414A Pending JP2009532394A (ja) | 2006-04-04 | 2007-04-04 | ポリペプチドの濃縮方法 |
| JP2009162789A Active JP5384232B2 (ja) | 2006-04-04 | 2009-07-09 | ポリペプチドの濃縮方法 |
| JP2013123735A Pending JP2013236633A (ja) | 2006-04-04 | 2013-06-12 | ポリペプチドの濃縮方法 |
| JP2013207384A Active JP5878152B2 (ja) | 2006-04-04 | 2013-10-02 | ポリペプチドの濃縮方法 |
| JP2013207365A Withdrawn JP2014058521A (ja) | 2006-04-04 | 2013-10-02 | ポリペプチドの濃縮方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (6) | US20090246187A1 (enExample) |
| EP (4) | EP2004672B1 (enExample) |
| JP (6) | JP2009532394A (enExample) |
| KR (3) | KR20150103339A (enExample) |
| CN (1) | CN105233276A (enExample) |
| AU (2) | AU2007234195B2 (enExample) |
| BR (1) | BRPI0709737A2 (enExample) |
| CA (3) | CA2644642C (enExample) |
| DK (1) | DK2628746T3 (enExample) |
| ES (3) | ES2713488T3 (enExample) |
| HU (1) | HUE042402T2 (enExample) |
| IL (4) | IL194267A (enExample) |
| MX (1) | MX2008012748A (enExample) |
| NO (3) | NO347673B1 (enExample) |
| NZ (7) | NZ607595A (enExample) |
| PL (3) | PL2631242T3 (enExample) |
| PT (1) | PT2628746T (enExample) |
| SI (1) | SI2628746T1 (enExample) |
| WO (1) | WO2007112757A2 (enExample) |
| ZA (2) | ZA200805346B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ548871A (en) | 2004-01-30 | 2009-06-26 | Shire Pharmaceuticals Ireland | Use of arylsulfatase A for treating metachromatic leukodystrophy |
| PL2631242T3 (pl) * | 2006-04-04 | 2023-03-20 | Takeda Pharmaceutical Company Limited | Sposób zatężania polipeptydu |
| EA022220B1 (ru) * | 2010-02-24 | 2015-11-30 | Сюменекс А/С | Способ получения и очистки рекомбинантной лизосомальной альфа-маннозидазы |
| DK2588130T3 (en) * | 2010-06-25 | 2016-10-24 | Shire Human Genetic Therapies | Cns delivery of therapeutic agents |
| PT3626258T (pt) | 2010-06-25 | 2021-10-19 | Shire Human Genetic Therapies | Métodos e composições para fornecimento ao snc de iduronato-2-sulfatase |
| MX2013000320A (es) | 2010-06-25 | 2013-06-05 | Shire Human Genetic Therapies | Composiciones y metodos para suministro al sistema nervioso central de heparan n-sulfatasa. |
| NZ605873A (en) * | 2010-06-25 | 2015-02-27 | Shire Human Genetic Therapies | Methods and compositions for cns delivery of arylsulfatase a |
| US10336992B2 (en) | 2011-07-08 | 2019-07-02 | Shire Human Genetic Therapies, Inc. | Methods for purification of arylsulfatase A |
| WO2013096899A2 (en) | 2011-12-23 | 2013-06-27 | Shire Human Genetic Therapies, Inc. | Stable formulations for cns delivery of arylsulfatase a |
| NZ707753A (en) * | 2012-11-13 | 2019-07-26 | Chiesi Farm Spa | Purification of recombinant human galactocerebroside β-galactosidase (rhgalc) |
| EP2932274B1 (en) * | 2012-12-11 | 2020-01-15 | Centogene AG | Method for the diagnosis of metachromatic leukodystrophy |
| CN119979504A (zh) | 2013-01-09 | 2025-05-13 | 武田药品工业株式会社 | 含用于纯化芳基硫酸酯酶a的方法 |
| EA037906B1 (ru) | 2013-03-15 | 2021-06-04 | Биовератив Терапьютикс Инк. | Препараты полипептида фактора ix |
| SG10201913735SA (en) | 2014-03-24 | 2020-03-30 | Bioverativ Therapeutics Inc | Lyophilized factor ix formulations |
| US11584777B2 (en) | 2017-08-31 | 2023-02-21 | Green Cross Corporation | Method for purifying a sulfatase protein |
| KR102290596B1 (ko) * | 2020-09-10 | 2021-08-19 | 주식회사 파이안바이오테크놀로지 | 분리된 미토콘드리아를 포함하는 주사용 조성물 및 이의 용도 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2041280A1 (en) | 1990-05-10 | 1991-11-11 | Yosuke Sawada | Arylsulfatase |
| NO960163D0 (no) | 1996-01-15 | 1996-01-15 | Thomas Berg | Mutasjonsdeteksjon av bovin |
| EP1049487B1 (en) | 1998-01-27 | 2002-05-22 | Hemebiotech A/S | Treatment of acute intermittent porphyria (aip) and other porphyric diseases |
| ES2421736T3 (es) * | 1998-06-09 | 2013-09-05 | Csl Behring Ag | Procedimiento para la preparación de inmunoglobulinas para administración intravenosa y otros productos inmunoglobulínicos |
| PL196770B1 (pl) * | 1998-06-09 | 2008-01-31 | Statens Seruminstitut | Sposób oczyszczania immunoglobuliny, produkt immunoglobuliny i jego zastosowanie |
| US6537777B1 (en) | 1998-07-27 | 2003-03-25 | Hemebiotech A/S | Human porphobilinogen deaminase sequences |
| AUPQ026799A0 (en) * | 1999-05-10 | 1999-06-03 | Csl Limited | Method of increasing protein stability by removing immunoglobulin aggregates |
| JP2003505057A (ja) | 1999-07-27 | 2003-02-12 | ヘム−バイオテック エイ／エス | ｒｈＰＢＧＤの製造及び急性間欠性ポルフィリン症（ＡＩＰ）及び他のポルフィリン症の患者を処置するための新規な治療方法 |
| US6812339B1 (en) * | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| EP1409695A2 (en) | 2000-11-15 | 2004-04-21 | Genzyme Corporation | Expression system for recombinant proteins |
| AU2002317701A1 (en) | 2001-06-07 | 2002-12-16 | Hemebiotech A/S | Production of recombinant human lysosomal alpha-mannosidase |
| AU2002317700A1 (en) * | 2001-06-07 | 2002-12-16 | Hemebiotech A/S | Production of recombinant human arylsulfatase a |
| WO2003002731A1 (en) * | 2001-06-29 | 2003-01-09 | Hemebiotech A/S | A PROCESS FOR PURIFICATION OF RECOMBINANT PORPHOBILINOGEN DEAMINASE (rhPBGD) |
| US7232670B2 (en) * | 2001-09-28 | 2007-06-19 | St. Jude Children's Research Hospital | Targeting proteins to cells expressing mannose receptors via expression in insect cells |
| EP1463512B1 (en) | 2002-01-11 | 2014-05-28 | biOasis Technologies Inc. | Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes |
| WO2003066669A2 (en) * | 2002-02-04 | 2003-08-14 | Millipore Corporation | Process for removing protein aggregates and virus from a protein solution |
| CH694697A5 (de) | 2004-01-29 | 2005-06-15 | Koelbl Engineering Und Consult | Gummimehl-enthaltende Elastomerlegierungen. |
| NZ548871A (en) | 2004-01-30 | 2009-06-26 | Shire Pharmaceuticals Ireland | Use of arylsulfatase A for treating metachromatic leukodystrophy |
| WO2005094874A1 (en) | 2004-04-01 | 2005-10-13 | Zymenex A/S | Medical use of alpha-mannosidase |
| US20060051347A1 (en) * | 2004-09-09 | 2006-03-09 | Winter Charles M | Process for concentration of antibodies and therapeutic products thereof |
| PL2631242T3 (pl) * | 2006-04-04 | 2023-03-20 | Takeda Pharmaceutical Company Limited | Sposób zatężania polipeptydu |
-
2007
- 2007-04-04 PL PL13167428.5T patent/PL2631242T3/pl unknown
- 2007-04-04 EP EP07711305.8A patent/EP2004672B1/en active Active
- 2007-04-04 WO PCT/DK2007/000177 patent/WO2007112757A2/en not_active Ceased
- 2007-04-04 CN CN201510510807.4A patent/CN105233276A/zh active Pending
- 2007-04-04 CA CA2644642A patent/CA2644642C/en active Active
- 2007-04-04 KR KR1020157023398A patent/KR20150103339A/ko not_active Ceased
- 2007-04-04 AU AU2007234195A patent/AU2007234195B2/en active Active
- 2007-04-04 CA CA2882501A patent/CA2882501C/en active Active
- 2007-04-04 NZ NZ607595A patent/NZ607595A/en unknown
- 2007-04-04 ES ES13167427T patent/ES2713488T3/es active Active
- 2007-04-04 BR BRPI0709737-9A patent/BRPI0709737A2/pt not_active Application Discontinuation
- 2007-04-04 PL PL13167427T patent/PL2628746T3/pl unknown
- 2007-04-04 JP JP2009503414A patent/JP2009532394A/ja active Pending
- 2007-04-04 KR KR1020087026971A patent/KR101504969B1/ko active Active
- 2007-04-04 CA CA2632528A patent/CA2632528C/en active Active
- 2007-04-04 HU HUE13167427A patent/HUE042402T2/hu unknown
- 2007-04-04 EP EP13167428.5A patent/EP2631242B1/en active Active
- 2007-04-04 NO NO20211305A patent/NO347673B1/no unknown
- 2007-04-04 KR KR1020147010563A patent/KR20140057678A/ko not_active Ceased
- 2007-04-04 MX MX2008012748A patent/MX2008012748A/es active IP Right Grant
- 2007-04-04 NZ NZ588903A patent/NZ588903A/xx unknown
- 2007-04-04 EP EP08166902.0A patent/EP2100898B1/en active Active
- 2007-04-04 NZ NZ571610A patent/NZ571610A/en unknown
- 2007-04-04 US US12/295,848 patent/US20090246187A1/en not_active Abandoned
- 2007-04-04 PL PL08166902T patent/PL2100898T3/pl unknown
- 2007-04-04 DK DK13167427.7T patent/DK2628746T3/en active
- 2007-04-04 EP EP13167427.7A patent/EP2628746B1/en active Active
- 2007-04-04 SI SI200732097T patent/SI2628746T1/sl unknown
- 2007-04-04 NZ NZ597548A patent/NZ597548A/xx unknown
- 2007-04-04 NZ NZ582045A patent/NZ582045A/en unknown
- 2007-04-04 NZ NZ568728A patent/NZ568728A/en unknown
- 2007-04-04 PT PT13167427T patent/PT2628746T/pt unknown
- 2007-04-04 ES ES08166902T patent/ES2744499T3/es active Active
- 2007-04-04 NZ NZ62312307A patent/NZ623123A/en unknown
- 2007-04-04 ES ES13167428T patent/ES2928096T3/es active Active
-
2008
- 2008-05-30 NO NO20082510A patent/NO20082510L/no not_active Application Discontinuation
- 2008-06-19 ZA ZA2008/05346A patent/ZA200805346B/en unknown
- 2008-09-22 IL IL194267A patent/IL194267A/en active IP Right Grant
- 2008-09-26 AU AU2008229659A patent/AU2008229659B2/en active Active
- 2008-11-07 ZA ZA2008/09540A patent/ZA200809540B/en unknown
- 2008-11-12 NO NO20084776A patent/NO346368B1/no unknown
-
2009
- 2009-07-09 JP JP2009162789A patent/JP5384232B2/ja active Active
-
2011
- 2011-03-24 IL IL211905A patent/IL211905A0/en unknown
- 2011-04-26 US US13/094,321 patent/US8809055B2/en active Active
-
2013
- 2013-06-12 JP JP2013123735A patent/JP2013236633A/ja active Pending
- 2013-10-02 JP JP2013207384A patent/JP5878152B2/ja active Active
- 2013-10-02 JP JP2013207365A patent/JP2014058521A/ja not_active Withdrawn
-
2014
- 2014-07-01 US US14/321,642 patent/US20140314735A1/en not_active Abandoned
- 2014-11-30 IL IL235982A patent/IL235982A0/en unknown
-
2015
- 2015-09-16 IL IL241654A patent/IL241654B/en active IP Right Grant
- 2015-11-16 JP JP2015223865A patent/JP2016104000A/ja active Pending
-
2016
- 2016-02-11 US US15/041,841 patent/US9713634B2/en active Active
-
2017
- 2017-03-29 US US15/473,460 patent/US20170202927A1/en not_active Abandoned
- 2017-05-03 US US15/585,916 patent/US20180289777A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016104000A5 (enExample) | ||
| JP2013236633A5 (enExample) | ||
| JP6882450B2 (ja) | 脂肪由来幹細胞から抽出されたエキソソームを有効成分として含む肺線維症の予防または治療用の組成物 | |
| CN114085273B (zh) | 病毒样颗粒的纯化 | |
| JP2022137183A5 (enExample) | ||
| AR076800A1 (es) | Metodo para producir una preparacion de inmunoglobulina con un alto rendimiento | |
| HRP20220250T1 (hr) | Modificirani nukleozidi, nukleotidi i nukleinske kiseline, te njihove uporabe | |
| CN108478600B (zh) | 间充质干细胞外泌体在制备防治骨质疏松症药物中的应用 | |
| JP2013535468A5 (enExample) | ||
| JP2019504030A5 (enExample) | ||
| CA2482512A1 (en) | Improved viral purification methods | |
| JP2015517489A5 (enExample) | ||
| JP2013528183A5 (enExample) | ||
| AR113257A1 (es) | Virus chikungunya inmunogénico | |
| JP2016501274A (ja) | 高純度の組換えヒト血清アルブミンを単離、精製するクロマトグラフ法 | |
| DE69023648T3 (de) | Herstellung eines virusimpfstoffes | |
| JP2015509506A5 (enExample) | ||
| JP2018505882A5 (enExample) | ||
| TW201348248A (zh) | 來自血漿中的免疫球蛋白之ｉ－ｉｖ－１部分沉澱 | |
| KR20100017594A (ko) | 바이러스 정제를 위한 연속 초원심분리용 당 용액의 제조 | |
| EP2640410B1 (de) | Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase | |
| JP2005538055A (ja) | タンジンの総フェノール酸の調製法およびその使用法 | |
| JP2020523398A5 (enExample) | ||
| JP6514412B2 (ja) | ヒト血漿由来ｂ型肝炎免疫グロブリン製剤の製造方法 | |
| MX2022002331A (es) | Nuevas formas solidas de acetato de[(1s)-1-[(2s,4r,5r)-5-(5-amino- 2-oxo-tiazolo[4,5-d]pirimidin-3-il)-4-hidroxi tetrahidrofuran-2-il]propilo]. |